Ovarian Cancer

ePRO Tool Improves Symptom Management in an Outpatient Gynecologic Cancer Clinic

By

Susan Moench, PhD, PA-C

Publish Date April 1, 2019

Investigators sought to determine if electronic patient-reported outcome tools with the PROMIS network improved identifying patients with severe symptoms and increased referrals to ancillary support services.

Managing Late and Long-Term Effects of Gynecologic Cancer and Its Treatment

By

Susan Moench, PhD, PA-C

Publish Date March 21, 2019

Psychosocial sexuality concerns relating to sexuality, and physical problems, including lymphedemlymphedema anda, and urinary and bowel dysfunction, are common in survivors of gynecologic cancer.

Survey Demonstrates Implicit Bias Toward Cervical Cancer Diagnoses Among Nurses, Women

By

Susan Moench, PhD, PA-C

Publish Date February 19, 2019

Survey sought to assess the relative implicit biases of gynecologic healthcare providers regarding women with diagnoses of cervical vs ovarian cancer.

Imported Doxorubicin Similar to US FDA-Approved Brand in Relapsed/Refractory Ovarian Cancer

By

Tiffany Garbutt, PhD

Publish Date January 9, 2019

This retrospective analysis determined the effect of Doxil vs Lipodox brands of doxorubicin, used for the treatment of recurrent or refractory ovarian cancer.

Low-Dose Aspirin May Lower Ovarian Cancer Risk

Publish Date October 23, 2018

Inverse association for low-dose but not standard-dose aspirin with ovarian cancer risk.

Ovarian Cancer Clinical Trials

Clinical Trial: Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

Clinical Trial: Prophylactic Salpingectomy With Delayed Oophorectomy

Clinical Trial: Interactive Educational Website for Women With Ovarian Cancer & Caregivers

Clinical Trial: Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Clinical Trial: AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer